Centre for Blood Research
@cbr-uoy.bsky.social
We aim to translate research into the clinic. Together we are making a real-life impact on people living with blood cancers and disorders.
Blood cancer patients faced higher COVID-19 mortality, but shielding & vaccines saved lives. Some subgroups need better protection strategies for future pandemics
November 18, 2025 at 1:21 PM
Blood cancer patients faced higher COVID-19 mortality, but shielding & vaccines saved lives. Some subgroups need better protection strategies for future pandemics
Vaccination helped:
There was a clear benefit overall, but limited effect in CLL & MCL patients. The findings suggest tailored strategies for vulnerable groups that are important beyond COVID-19.
#Immunology #CancerCare
There was a clear benefit overall, but limited effect in CLL & MCL patients. The findings suggest tailored strategies for vulnerable groups that are important beyond COVID-19.
#Immunology #CancerCare
November 18, 2025 at 1:21 PM
Vaccination helped:
There was a clear benefit overall, but limited effect in CLL & MCL patients. The findings suggest tailored strategies for vulnerable groups that are important beyond COVID-19.
#Immunology #CancerCare
There was a clear benefit overall, but limited effect in CLL & MCL patients. The findings suggest tailored strategies for vulnerable groups that are important beyond COVID-19.
#Immunology #CancerCare
Shielding mattered:
Early excess deaths in patients with MBL (premalignancy) occurred because they weren’t advised to shield initially - unlike those with malignancies. This showcases a gap in healthcare-related policy.
#PublicHealth
Early excess deaths in patients with MBL (premalignancy) occurred because they weren’t advised to shield initially - unlike those with malignancies. This showcases a gap in healthcare-related policy.
#PublicHealth
November 18, 2025 at 1:21 PM
Shielding mattered:
Early excess deaths in patients with MBL (premalignancy) occurred because they weren’t advised to shield initially - unlike those with malignancies. This showcases a gap in healthcare-related policy.
#PublicHealth
Early excess deaths in patients with MBL (premalignancy) occurred because they weren’t advised to shield initially - unlike those with malignancies. This showcases a gap in healthcare-related policy.
#PublicHealth
Mortality risk:
Haematology patients: 2.59% COVID-19 deaths
General population: 1.65%
Risks were higher in men, older age, and those with co-morbidities.
#BloodCancer #Epidemiology
Haematology patients: 2.59% COVID-19 deaths
General population: 1.65%
Risks were higher in men, older age, and those with co-morbidities.
#BloodCancer #Epidemiology
November 18, 2025 at 1:21 PM
Mortality risk:
Haematology patients: 2.59% COVID-19 deaths
General population: 1.65%
Risks were higher in men, older age, and those with co-morbidities.
#BloodCancer #Epidemiology
Haematology patients: 2.59% COVID-19 deaths
General population: 1.65%
Risks were higher in men, older age, and those with co-morbidities.
#BloodCancer #Epidemiology
Read more about the research in the press coverage on our website: york.ac.uk/news-and-eve...
You can also read the publication here: haematologica.org/article/view...
You can also read the publication here: haematologica.org/article/view...
Survival in people with myeloma nearly doubled since 2005
People diagnosed with multiple myeloma – one of the most common forms of blood cancer – are now living nearly twice as long on average as they were in 2005, according to a new study.
york.ac.uk
September 10, 2025 at 2:27 PM
Read more about the research in the press coverage on our website: york.ac.uk/news-and-eve...
You can also read the publication here: haematologica.org/article/view...
You can also read the publication here: haematologica.org/article/view...
The findings have been published during Blood Cancer Awareness Month. Myeloma affects around 6,300 people in the UK every year, making up around 2% of all cancer cases. Currently there is no cure, but treatment can help to manage symptoms and extend life
September 10, 2025 at 2:27 PM
The findings have been published during Blood Cancer Awareness Month. Myeloma affects around 6,300 people in the UK every year, making up around 2% of all cancer cases. Currently there is no cure, but treatment can help to manage symptoms and extend life
This research was led by our leaders in Health Sciences
& funded by @cancerresearchuk.org
and @bloodcanceruk.bsky.social
The study found that median survival for people with myeloma rose from 2.4 years in 2005 to 4.5 years in 2019
& funded by @cancerresearchuk.org
and @bloodcanceruk.bsky.social
The study found that median survival for people with myeloma rose from 2.4 years in 2005 to 4.5 years in 2019
September 10, 2025 at 2:27 PM
This research was led by our leaders in Health Sciences
& funded by @cancerresearchuk.org
and @bloodcanceruk.bsky.social
The study found that median survival for people with myeloma rose from 2.4 years in 2005 to 4.5 years in 2019
& funded by @cancerresearchuk.org
and @bloodcanceruk.bsky.social
The study found that median survival for people with myeloma rose from 2.4 years in 2005 to 4.5 years in 2019
One rose will be sent to London on behalf of each person who pledges their support, with each rose representing the region’s call for better prevention, earlier diagnosis, improved treatment & fairer research funding for Yorkshire
July 18, 2025 at 1:04 PM
One rose will be sent to London on behalf of each person who pledges their support, with each rose representing the region’s call for better prevention, earlier diagnosis, improved treatment & fairer research funding for Yorkshire
Along with Yorkshire Cancer Research, Generation Research are urging people to 'Stand with Yorkshire' and call for the Government to invest now for a cancer-free future in Yorkshire, and beyond
Send a white rose to London:
www.yorkshirecancerresearch.org.uk/campaigning/...
Send a white rose to London:
www.yorkshirecancerresearch.org.uk/campaigning/...
Send a white rose to London for a cancer-free future - Yorkshire Cancer Research
We're urging the Government to invest now for a cancer-free future - in Yorkshire and beyond. To do it, we’ll deliver hundreds of white roses to Health Secretary Wes Streeting, with the name of every...
www.yorkshirecancerresearch.org.uk
July 18, 2025 at 1:04 PM
Along with Yorkshire Cancer Research, Generation Research are urging people to 'Stand with Yorkshire' and call for the Government to invest now for a cancer-free future in Yorkshire, and beyond
Send a white rose to London:
www.yorkshirecancerresearch.org.uk/campaigning/...
Send a white rose to London:
www.yorkshirecancerresearch.org.uk/campaigning/...
Generation Research Founder Jillian Barlow answered the questions:
❔ What do we mean by clinical research?
❔How can we build better research ecosystems & what does "better" mean?
❔How do we solve inequity in healthcare by supporting biomedical scientists from diverse backgrounds?
❔ What do we mean by clinical research?
❔How can we build better research ecosystems & what does "better" mean?
❔How do we solve inequity in healthcare by supporting biomedical scientists from diverse backgrounds?
July 18, 2025 at 1:04 PM
Generation Research Founder Jillian Barlow answered the questions:
❔ What do we mean by clinical research?
❔How can we build better research ecosystems & what does "better" mean?
❔How do we solve inequity in healthcare by supporting biomedical scientists from diverse backgrounds?
❔ What do we mean by clinical research?
❔How can we build better research ecosystems & what does "better" mean?
❔How do we solve inequity in healthcare by supporting biomedical scientists from diverse backgrounds?
...through initaitives such as Active Together (Liam Humphreys), Yorkshire Lung Screening Trial (with Matthew Callister) and Yorkshire Enhanced Stop Smoking Study
This is all dependent on innovative regional clinical research
But who are our future clinical researchers?
This is all dependent on innovative regional clinical research
But who are our future clinical researchers?
July 18, 2025 at 1:04 PM
...through initaitives such as Active Together (Liam Humphreys), Yorkshire Lung Screening Trial (with Matthew Callister) and Yorkshire Enhanced Stop Smoking Study
This is all dependent on innovative regional clinical research
But who are our future clinical researchers?
This is all dependent on innovative regional clinical research
But who are our future clinical researchers?